GLP1R and chronic kidney disease: The 2024 ADA guidelines recommend GLP-1 RAs and SGLT-2is, with or without metformin depending on glycemic control needs, as initial therapeutic agents for patients with T2DM and comorbid ASCVD, heart failure, or chronic kidney disease (American Diabetes Association, 2024).